Adagene Inc.
ADAG- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001818838
In the last 90 days, Adagene Inc. insiders filed 4 open-market purchases and 0 sales; 35 institutions reported holding it in 13F filings for Q2 2026, worth $81.0M in total; no superinvestor holds it.
Q4 2021 vs. Q3 2021
How the institutions holding Adagene Inc. changed between Q3 2021 and Q4 2021.
All holders in Q4 2021All holders in Q3 2021
| Measure | Q3 2021 | Q4 2021 | Change |
|---|---|---|---|
| Holders | 19 | 16 | −3 |
| Shares | 8.79M | 8.37M | −413.1K (−4.7%) |
| Value | $126.6M | $67.3M | −$59.3M (−46.8%) |
New holders (2)
Institutions that held Adagene Inc. at the end of Q4 2021 but not at the end of Q3 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Citadel Advisors LLC | 16,753 | $134.0K | 0.00% |
| Tower Research Capital LLC (TRC) | 1,278 | $10.0K | 0.00% |
Sold out (5)
Institutions that held Adagene Inc. at the end of Q3 2021 and filed for Q4 2021 without it.
| Institution | Shares, Q3 2021 | Value, Q3 2021 |
|---|---|---|
| CloudAlpha Capital Management Limited/Hong Kong | 300,000 | $4.31M |
| Suvretta Capital Management, LLC | 42,722 | $614.0K |
| ExodusPoint Capital Management, LP | 32,243 | $463.0K |
| UBS Group AG | 1,225 | $18.0K |
| Citigroup Inc | 654 | $9.00K |